ExodusPoint Capital Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

ExodusPoint Capital Management’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.24M	Sell	120,310 -92,686	-44%	-$1.54M	0.02%	746
2025 Q4	$2.81M	Buy	+212,996	New	+$2.51M	0.02%	658
2025 Q3	–	Sell	-25,313	Closed	-$1.32M	–	1840
2025 Q2	$1.2M	Buy	+25,313	New	+$1.03M	0.01%	905
2024 Q4	–	Sell	-16,855	Closed	-$850K	–	1841
2024 Q3	$850K	Buy	+16,855	New	+$790K	0.01%	1013
2024 Q1	–	Sell	-28,417	Closed	-$1.72M	–	1793
2023 Q4	$1.72M	Sell	28,417 -16,764	-37%	-$864K	0.01%	629
2023 Q3	$2.58M	Buy	+45,181	New	+$2.49M	0.02%	598
2022 Q1	–	Sell	-25,200	Closed	-$249K	–	2494
2021 Q4	$249K	Buy	25,200 +200	+0.8%	+$1.99K	﹤0.01%	1728
2021 Q3	$247K	Hold	25,000	–	–	﹤0.01%	1698
2021 Q2	$259K	Hold	25,000	–	–	﹤0.01%	1828
2021 Q1	$255K	Sell	25,000 -9,551	-28%	-$105K	﹤0.01%	1760
2020 Q4	$393K	Buy	+34,551	New	+$367K	﹤0.01%	1393

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

ExodusPoint Capital Management's MLTX Position: Q1 2026 in Review

ExodusPoint Capital Management reduced its MoonLake Immunotherapeutics (MLTX) stake by 44% in Q1 2026, selling an estimated $1.54M and leaving 120,310 shares worth $2.24M. The position accounts for 0.02% of the portfolio, ranked #746.

ExodusPoint Capital Management first reported a position in MLTX in Q4 2020 and has held it in 11 quarters since. The position peaked at $2.81M in Q4 2025. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

ExodusPoint Capital Management held 120,310 shares of MoonLake Immunotherapeutics worth $2.24M as of Q1 2026.
ExodusPoint Capital Management sold 92,686 MoonLake Immunotherapeutics shares in Q1 2026, an estimated $1.54M.
MoonLake Immunotherapeutics made up 0.02% of ExodusPoint Capital Management's portfolio in Q1 2026, its #746 holding.
ExodusPoint Capital Management first reported a position in MoonLake Immunotherapeutics in Q4 2020 and has held it in 11 quarters since.
ExodusPoint Capital Management's MoonLake Immunotherapeutics position peaked at $2.81M in Q4 2025.
147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.